Pharmacogenetics of cardiovascular drug therapy

Keyphrases

• Pharmacogenetics 100%
• Drug Therapy 100%
• Cardiovascular Drugs 100%
• Coumarin 60%
• CYP2C9 40%
• Statins 40%
• Platelet Aggregation Inhibitors 40%
• Clinical Trials 20%
• Leading Causes of Death 20%
• Polymorphism 20%
• VKORC1 20%
• Oral Anticoagulants 20%
• Environmental Factors 20%
• Risk Reduction 20%
• Genetic Analysis 20%
• Genetic Testing 20%
• Drug Class 20%
• Developed Countries 20%
• SNP 20%
• Statistical Methods 20%
• Genetic Variability 20%
• Alpha 3 20%
• Cardiovascular Disease 20%
• Personalized Medicine 20%
• Adducin 20%
• Anticoagulant Therapy 20%
• Reductase 20%
• Aspirin 20%
• Cholesterol-lowering Drugs 20%
• Variability in Response 20%
• Pharmacogenetic Study 20%
• Inter-individual Variation 20%
• Study Power 20%
• Cyclooxygenase-1 (COX-1) 20%
• Drug Response 20%
• Cardiovascular Risk 20%
• Usage Factor 20%
• Concomitant Drug Use 20%
• Pharmacogenetic Research 20%
• Pharmacotherapeutic Interventions 20%
• 3-hydroxy-3-methylglutaryl-CoA Reductase 20%
• Commonly Prescribed Drugs 20%
• Power Study 20%
• Vitamin K 20%
• Addressing Issues 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacogenetics 100%
• Pharmacotherapy 100%
• Cardiovascular Agent 100%
• Coumarin Derivative 60%
• Antihypertensive 60%
• Anticoagulant Agent 40%
• CYP2C9 40%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 40%
• Oxidoreductase 40%
• Antithrombocytic Agent 40%
• Cardiovascular Disease 40%
• Clinical Trial 20%
• Alpha Adducin 20%
• Concomitant Drug 20%
• Phytomenadione 20%
• Acetylsalicylic Acid 20%
• Hypocholesterolemic Agent 20%